UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of Earliest Event Reported):
December
24, 2015 (May 30, 2015)
PetLife
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Nevada |
|
000-52445 |
|
33-1133537 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification
No.) |
433
N. Camden Dr., Beverly Hills, CA |
|
90210 |
(Address
of Principal Executive Offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (310) 279-5152
Clear
TV Ventures, Inc.
(formerly
Eco Ventures Group, Inc.)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions.
[ ] |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
[ ] |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
[ ] |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
[ ] |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item
4.01 Changes in Registrant’s Certifying Accountant.
(a)
On May 30, 2015 Petlife Pharmaceuticals, Inc., formerly Clear TV Ventures, Inc., (the “Registrant” or the “Company”)
was notified by RBSM LLP (” RBSM”) that the firm resigned as the Company’s independent registered public accounting
firm .The Company engaged LBB & Associates, Ltd., LLP (“LBB”), as its new independent registered public accounting
firm on December 1, 2015. The decision to engage the LBB as the Company’s independent registered public accounting firm
was approved by the Company’s Board of Directors. Except as noted in the paragraph immediately below, the reports of RBSM
on the Company’s financial statements for the years ended August 31, 2013 and August 31, 2012 and for the period from November
9, 2010 (date of inception) through August 31, 2013.did not contain an adverse opinion or disclaimer of opinion, and such reports
were not qualified or modified as to uncertainty, audit scope, or accounting principle.
The
reports of the RBSM on the Company’s financial statements as of and for the years ended August 31, 2013 and August 31, 2012
and for the period from November 9, 2010 (date of inception) through August 31, 2013 contained explanatory paragraphs which noted
that there was substantial doubt as to the Company’s ability to continue as a going concern as the Company had not generated
sufficient cash flow from operations to meet its obligations.
During
the years ended August 31, 2013 and August 31, 2012 and for the period from November 9, 2010 (date of inception) through August
31, 2013., and through May 30, 2015, the Company has not had any disagreements with RBSM on any matter of accounting principles
or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to RBSM’s
satisfaction, would have caused them to make reference thereto in their reports on the Company’s financial statements for
such periods.
During
the years ended August 31, 2013 and August 31, 2012 and for the period from November 9, 2010 (date of inception) through August
31, 2013, and through May 30, 2015, there were no reportable events, as defined in Item 304(a)(1)(v) of Regulation S-K.
The
Company provided RBSM with a copy of this disclosure set forth under this Item 4.01 and was requested to furnish a letter addressed
to the Securities & Exchange Commission stating whether or not it agrees with the above statements.
A
copy of the letter from RBSM is attached hereto as Exhibit 16.1
New
independent registered public accounting firm
Effective
December 1, 2015 (the “Engagement Date”), the Company engaged LBB & Associates Ltd., LLP (“LBB”) as
its independent registered public accounting firm for the Company’s fiscal years ended August 31, 2014 and August 31, 2015.
The decision to engage LBB as the Company’s independent registered public accounting firm was approved by the Company’s
Board of Directors.
During
the two most recent fiscal years and through the Engagement Date, the Company has not consulted with LBB regarding either:
|
1. |
the application
of accounting principles to any specified transaction, either completed or proposed, or the type of audit opinion that might be
rendered on the Company’s financial statements, and neither a written report was provided to the Company nor oral advice
was provided that LBB concluded was an important factor considered by the Company in reaching a decision as to the accounting,
auditing or financial reporting issue; or |
|
2. | any matter
that was either the subject of a disagreement (as defined in paragraph (a)(1)(iv) of Item 304 of Regulation S-K and the related
instructions thereto) or a reportable event (as described in paragraph (a)(1)(v) of Item 304 of Regulation S-K). |
Item
9.01 Financial Statements and Exhibits
Exhibit
No. |
|
Description
of Exhibit |
|
|
|
16.1 |
|
Letter
from RBSM LLP |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
PETLIFE PHARMACEUTICALS, INC.
(Registrant)
Dated:
December 28, 2015 |
By: |
/s/
Dr. Arthur Mikaelian |
|
|
Dr.
Arthur Mikaelian |
|
|
President |
Exhibit
16.1
RBSM,
LLP
NEW
YORK, NEW YORK
December
24, 2015
Securities
and Exchange Commission
100
F Street, N.W.
Washington,
DC 20549-7561
Dear
Sirs/Madams:
We
have read Item 4.01 of the Petlife Pharmaceuticals, Inc., formerly Clear TV Ventures, Inc., (the “Company”) Form 8-K
dated May 30, 2015, and are in agreement with the statements relating only to RBSM, LLP contained therein. We have no basis to
agree or disagree with other statements of the Company contained therein
Very
truly yours,
/s/
RBSM LLP |
|
New
York, New York |
|
Petlife Pharmaceuticals (CE) (USOTC:PTLF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Petlife Pharmaceuticals (CE) (USOTC:PTLF)
Historical Stock Chart
From Jul 2023 to Jul 2024